The impact of O-GlcNAc by way of FGF23 will open new avenues for research in lung diseases associated with chronic airway inflammation such as COPD, cystic fibrosis, and asthma as well as metabolic disorders including diabetes and heart failure. Here, FGF23 is linked to diabetes mellitus.